USD 0.0847
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| MMIRF | 54 | -4.0 | 546.6 | 46.5 | 41.2 | 142 | -36.7 | 389.3 | 14.5 | 53.4 |
| S&P 500 | 0.5 | -0.8 | 2.8 | 4.4 | 11.7 | 23.3 | 34.5 | 84.9 | 204.3 | 34278.1 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | MMIRF |
| name | MedMira Inc. |
| price | 0.0847 |
| changes percentage | 54 |
| change | 0.0297 |
| day low | 0.055 |
| day high | 0.0847 |
| year high | 0.09 |
| year low | 0.013 |
| market cap | 64228603 |
| price avg 50 | 0.05235 |
| price avg 200 | 0.054906 |
| exchange | PNK |
| volume | 1000 |
| avg volume | 2591 |
| open | 0.055 |
| previous close | 0.055 |
| eps | -0.02 |
| pe | -4.23 |
| earnings announcement | 2025-03-31T20:00:00.000+0000 |
| shares outstanding | 758307000 |
| timestamp | 2025-01-29 20:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 412568 | 432529 | -4.61 |
| gross profit | 226489 | 300382 | -24.60 |
| gross profit ratio | 0.55 | 0.69 | -20.95 |
| research and development expenses | 476891 | 470683 | 1.32 |
| operating expenses | 2799485 | 2244700 | 24.72 |
| interest income | -14000 | 885522 | -101.58 |
| interest expense | 882413 | 0 | NaN |
| ebitda | -2134356 | -1577239 | -35.32 |
| ebitdaratio | -5.17 | -3.65 | -41.87 |
| operating income | -2572996 | -1944318 | -32.33 |
| operating income ratio | -6.24 | -4.5 | -38.74 |
| net income | -3326321 | -2675658 | -24.32 |
| net income ratio | -8.06 | -6.19 | -30.33 |
| eps | -0.0 | -0.0 | -20.00 |
Revenue Growth: revenue decreased to 0 million in 2024 from 0 million in 2023 representing a change of -4.61%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 0 million in 2024 from 0 million in 2023 representing a change of -24.6%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 3 million in 2024 from 2 million in 2023 representing a change of 24.72%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 0 million in 2024 from 0 million in 2023 representing a change of 1.32%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -2 million in 2024 from -2 million in 2023 representing a change of -35.32%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -3 million in 2024 from -2 million in 2023 representing a change of -32.33%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -3 million in 2024 from -3 million in 2023 representing a change of -24.32%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| revenue | 61723 | 64462 | -4.25 |
| gross profit | 52778 | 37414 | 41.06 |
| gross profit ratio | 0.86 | 0.58 | 47.32 |
| research and development expenses | 423253 | 105902 | 299.66 |
| operating expenses | 1111283 | 897984 | 23.75 |
| interest income | 0 | -14000 | 100.00 |
| interest expense | 242044 | 300455 | -19.44 |
| ebitda | -978494 | -733038 | -33.48 |
| ebitdaratio | -15.85 | -11.37 | -39.41 |
| operating income | -1058505 | -860570 | -23.00 |
| operating income ratio | -17.15 | -13.35 | -28.46 |
| net income | -1300549 | -1175025 | -10.68 |
| net income ratio | -21.07 | -18.23 | -15.59 |
| eps | -0.0 | -0.0 | -11.76 |
Revenue Growth: revenue decreased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of -4.25%. This indicates a sales shrinking, which is a negative sign for the company.
Operating Income: Operating income decreased to -1 million in 2025Q1 from -1 million in 2024Q4 representing a change of -23.0%. The decrease in operating income indicates worse operational performance and decreased profitability.
Gross Profit: Gross Profit increased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of 41.06%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of 299.66%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 1 million in 2025Q1 from 1 million in 2024Q4 representing a change of 23.75%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -1 million in 2025Q1 from -1 million in 2024Q4 representing a change of -33.48%. The increase in EBITDA indicates improved operational efficiency and profitability.
Net Income: Net income increased to -1 million in 2025Q1 from -1 million in 2024Q4 representing a change of -10.68%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 6069669 | 3651802 | 66.21 |
| total liabilities | 24106274 | 18683457 | 29.02 |
| total equity | -18036605 | -15031655 | -19.99 |
| cash and cash equivalents | 2097595 | 13178 | 15817.40 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 3677168 | 1692284 | 117.29 |
| total non current assets | 2392501 | 1959518 | 22.10 |
| total current liabilities | 20954127 | 15726229 | 33.24 |
| total non current liabilities | 3152147 | 2957228 | 6.59 |
| common stock | 68671091 | 68347220 | 0.47 |
| retained earnings | -101285424 | -97959103 | -3.40 |
| total debt | 9560312 | 9271202 | 3.12 |
Total Assets: Total Assets increased to 6 million in 2024 from 4 million in 2023 representing a change of 66.21%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 2 million in 2024 from 0 million in 2023 representing a change of 15817.4%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 4 million in 2024 from 2 million in 2023 representing a change of 117.29%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 69 in 2024 from 68 in 2023 representing a change of 0.47%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 24 million in 2024 from 19 million in 2023 representing a change of 29.02%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -18 million in 2024 from -15 million in 2023 representing a change of -19.99%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 21 million in 2024 from 16 million in 2023 representing a change of 33.24%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -101 million in 2024 from -98 million in 2023 representing a change of -3.4%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 10 million in 2024 from 9 million in 2023 representing a change of 3.12%. This indicates an increase in overall debt burden.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| total assets | 4992135 | 6069669 | -17.75 |
| total liabilities | 24329289 | 24106274 | 0.93 |
| total equity | -19337154 | -18036605 | -7.21 |
| cash and cash equivalents | 1055577 | 2097595 | -49.68 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 2677545 | 3677168 | -27.18 |
| total non current assets | 2314590 | 2392501 | -3.26 |
| total current liabilities | 21353307 | 20954127 | 1.91 |
| total non current liabilities | 2975982 | 3152147 | -5.59 |
| common stock | 68671091 | 68671091 | 0.00 |
| retained earnings | -102585973 | -101285424 | -1.28 |
| total debt | 9538337 | 9560312 | -0.23 |
Total Assets: Total Assets decreased to 5 million in 2025Q1 from 6 million in 2024Q4 representing a change of -17.75%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 24 million in 2025Q1 from 24 million in 2024Q4 representing a change of 0.93%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -19 million in 2025Q1 from -18 million in 2024Q4 representing a change of -7.21%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 1 million in 2025Q1 from 2 million in 2024Q4 representing a change of -49.68%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 3 million in 2025Q1 from 4 million in 2024Q4 representing a change of -27.18%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 21 million in 2025Q1 from 21 million in 2024Q4 representing a change of 1.91%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -103 million in 2025Q1 from -101 million in 2024Q4 representing a change of -1.28%. This indicates an accumulated losses.
Total Debt: Total Debt decreased to 10 million in 2025Q1 from 10 million in 2024Q4 representing a change of -0.23%. This indicates a reduction in overall debt burden.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0000000000 | |||
| net change in cash | 2084417 | -20283 | 10376.67 |
| operating cash flow | -2938521 | -1267750 | -131.79 |
| free cash flow | -3681056 | -1269017 | -190.07 |
| capital expenditure | -742535 | -1267 | -58505.76 |
| depreciation and amortization | 309552 | 212897 | 45.40 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts payables | -546125 | 513119 | -206.43 |
| inventory | 4389 | 19540 | -77.54 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -742535 | -1267 | -58505.76 |
| net cash used for investing activites | -742535 | -1267 | -58505.76 |
| debt repayment | 549682 | 972190 | -43.46 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 5765473 | 1248734 | 361.71 |
| cash at end of period | 2097595 | 13178 | 15817.40 |
| accounts receivables | 95541 | -11174 | 955.03 |
| cash at beginning of period | 13178 | 33461 | -60.62 |
Net Change in Cash: Net Change in Cash increased to 2 million in 2024 from 0 million in 2023 representing a change of 10376.67%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2024 from 0 million in 2023 representing a change of -58505.76%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Operating Cash Flow: Operating Cash Flow decreased to -3 million in 2024 from -1 million in 2023 representing a change of -131.79%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -4 million in 2024 from -1 million in 2023 representing a change of -190.07%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024 from 1 million in 2023 representing a change of -206.43%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2024 from 0 million in 2023 representing a change of 955.03%. This suggests that the company is less capable of collecting payments from its customers.
| 2025Q1 | 2024Q4 | Q/Q change % | |
|---|---|---|---|
| 0000000000 | |||
| operating cash flow | -997549 | -762551 | -30.82 |
| free cash flow | -997549 | -1505086 | 33.72 |
| capital expenditure | 0 | 0 | NaN |
| depreciation and amortization | 80011 | 141532 | -43.47 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 0 | 0 | NaN |
| accounts receivables | -21342 | 17900 | -219.23 |
| accounts payables | 0 | 0 | NaN |
| inventory | -6978 | 29046 | -124.02 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 0 | NaN |
| net cash used for investing activites | -2100 | -738724 | 99.72 |
| debt repayment | -42369 | 672539 | -106.30 |
| common stock issued | 0 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -42369 | 689750 | -106.14 |
| net change in cash | -1042018 | -811525 | -28.40 |
| cash at end of period | 1055577 | 2097595 | -49.68 |
| cash at beginning of period | 2097595 | 2909120 | -27.90 |
Net Change in Cash: Net Change in Cash decreased to -1 million in 2025Q1 from -1 million in 2024Q4 representing a change of -28.4%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -1 million in 2025Q1 from -1 million in 2024Q4 representing a change of -30.82%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -1 million in 2025Q1 from -2 million in 2024Q4 representing a change of 33.72%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2025Q1 from 0 million in 2024Q4 representing a change of -219.23%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-07-31 | 2023-07-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 0.0 | 0.0 | -4.95 |
| net income per share | -0.0 | -0.0 | -23.88 |
| operating cash flow per share | -0.0 | -0.0 | -130.98 |
| free cash flow per share | -0.01 | -0.0 | -189.06 |
| cash per share | 0.0 | 0.0 | 15761.85 |
| book value per share | -0.03 | -0.02 | -19.57 |
| tangible book value per share | -0.03 | -0.02 | -19.57 |
| shareholders equity per share | -0.03 | -0.02 | -19.57 |
| interest debt per share | 0.01 | 0.01 | 2.46 |
| market cap | 66489366.74 | 62770109.4 | 5.93 |
| enterprise value | 73952083.75 | 72028133.4 | 2.67 |
| pe ratio | -19.99 | -23.46 | 14.79 |
| price to sales ratio | 161.16 | 145.12 | 11.05 |
| pocfratio | -22.63 | -49.51 | 54.30 |
| pfcf ratio | -18.06 | -49.46 | 63.48 |
| pb ratio | -3.69 | -4.18 | 11.72 |
| ptb ratio | -3.69 | -4.18 | 11.72 |
| ev to sales | 179.25 | 166.53 | 7.64 |
| enterprise value over ebitda | -34.65 | -45.67 | 24.13 |
| ev to operating cash flow | -25.17 | -56.82 | 55.71 |
| ev to free cash flow | -20.09 | -56.76 | 64.60 |
| earnings yield | -0.05 | -0.04 | -17.36 |
| free cash flow yield | -0.06 | -0.02 | -173.85 |
| debt to equity | -0.53 | -0.62 | 14.06 |
| debt to assets | 1.58 | 2.54 | -37.96 |
| net debt to ebitda | -3.5 | -5.87 | 40.43 |
| current ratio | 0.18 | 0.11 | 63.08 |
| interest coverage | -2.92 | -2.2 | -32.80 |
| income quality | 0.88 | 0.47 | 86.45 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 2.9 | 1.95 | 48.85 |
| research and ddevelopement to revenue | 1.16 | 1.09 | 6.22 |
| intangibles to total assets | 0.0 | 0.0 | -39.84 |
| capex to operating cash flow | -0.25 | -0.0 | -25183.96 |
| capex to revenue | 1.8 | 0.0 | 61341.24 |
| capex to depreciation | 2.4 | 0.01 | 40206.61 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.05 | 0.04 | 21.71 |
| roic | 0.3 | 0.34 | -10.07 |
| return on tangible assets | -0.55 | -0.73 | 25.20 |
| graham net net | -0.03 | -0.03 | -19.07 |
| working capital | -17276959 | -14033945 | -23.11 |
| tangible asset value | -18036607 | -15031657 | -19.99 |
| net current asset value | -20429106 | -16991173 | -20.23 |
| invested capital | -14884458 | -12074427 | -23.27 |
| average receivables | 1379673.5 | 1398255.5 | -1.33 |
| average payables | 2989671 | 3006163.5 | -0.55 |
| average inventory | 180229.5 | 192194 | -6.23 |
| days sales outstanding | 1178.34 | 1204.58 | -2.18 |
| days payables outstanding | 5328.72 | 1372.89 | 288.14 |
| days of inventory on hand | 349.22 | 76.76 | 354.95 |
| receivables turnover | 0.31 | 0.3 | 2.23 |
| payables turnover | 0.07 | 0.27 | -74.24 |
| inventory turnover | 1.05 | 4.76 | -78.02 |
| roe | 0.18 | 0.18 | 3.61 |
| capex per share | 0.0 | 0.0 | 58301.24 |
ROE: Return on Equity (ROE) decreased to 0.18 on 2024-07-31 from 0.18 on 2023-07-31, representing a change of 3.61%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to -0.53 on 2024-07-31 from -0.62 on 2023-07-31, representing a change of 14.06%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -19.99 on 2024-07-31 from -23.46 on 2023-07-31, representing a change of 14.79%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 0.18 on 2024-07-31 from 0.11 on 2023-07-31, representing a change of 63.08%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. However, it's below 1, indicating potential liquidity issues.
| 2024-10-31 Q1 | 2024-07-31 Q4 | Q/Q change % | |
|---|---|---|---|
| MMIRF | |||
| calendar year | 2025 | 2024 | NaN |
| revenue per share | 0.0 | 0.0 | -4.18 |
| net income per share | -0.0 | -0.0 | -10.76 |
| operating cash flow per share | -0.0 | -0.0 | -30.91 |
| free cash flow per share | -0.0 | -0.0 | 33.68 |
| cash per share | 0.0 | 0.0 | -49.64 |
| book value per share | -0.03 | -0.03 | -7.28 |
| tangible book value per share | -0.03 | -0.03 | -7.28 |
| shareholders equity per share | -0.03 | -0.03 | -7.28 |
| interest debt per share | 0.01 | 0.01 | -0.75 |
| market cap | 56138447.28 | 66709239.4 | -15.85 |
| enterprise value | 64621207.28 | 74171956.4 | -12.88 |
| pe ratio | -10.79 | -14.19 | 23.97 |
| price to sales ratio | 909.52 | 1034.86 | -12.11 |
| pocfratio | -56.28 | -87.48 | 35.67 |
| pfcf ratio | -56.28 | -44.32 | -26.97 |
| pb ratio | -2.9 | -3.7 | 21.51 |
| ptb ratio | -2.9 | -3.7 | 21.51 |
| ev to sales | 1046.96 | 1150.63 | -9.01 |
| enterprise value over ebitda | -66.04 | -101.18 | 34.73 |
| ev to operating cash flow | -64.78 | -97.27 | 33.40 |
| ev to free cash flow | -64.78 | -49.28 | -31.45 |
| earnings yield | -0.02 | -0.02 | -31.52 |
| free cash flow yield | -0.02 | -0.02 | 21.24 |
| debt to equity | -0.49 | -0.53 | 6.94 |
| debt to assets | 1.91 | 1.58 | 21.31 |
| net debt to ebitda | -8.67 | -10.18 | 14.85 |
| current ratio | 0.13 | 0.18 | -28.55 |
| interest coverage | -4.37 | -2.86 | -52.68 |
| income quality | 0.77 | 0.65 | 18.19 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 5.54 | 7.52 | -26.40 |
| research and ddevelopement to revenue | 6.86 | 1.64 | 317.40 |
| intangibles to total assets | 0.0 | 0.0 | 21.58 |
| capex to operating cash flow | 0 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.03 | 0.03 | 9.01 |
| roic | 0.11 | 0.1 | 6.40 |
| return on tangible assets | -0.26 | -0.19 | -34.57 |
| graham net net | -0.03 | -0.03 | -6.02 |
| working capital | -18675762 | -17276959 | -8.10 |
| tangible asset value | -19337156 | -18036607 | -7.21 |
| net current asset value | -21651744 | -20429106 | -5.98 |
| invested capital | -16361172 | -14884458 | -9.92 |
| average receivables | 1342574 | 1340853 | 0.13 |
| average payables | 2720715 | 2737706 | -0.62 |
| average inventory | 181524 | 192558 | -5.73 |
| days sales outstanding | 1973.2 | 1859.56 | 6.11 |
| days payables outstanding | 27415.71 | 9039.31 | 203.29 |
| days of inventory on hand | 1861.51 | 592.4 | 214.23 |
| receivables turnover | 0.05 | 0.05 | -5.76 |
| payables turnover | 0.0 | 0.01 | -67.03 |
| inventory turnover | 0.05 | 0.15 | -68.18 |
| roe | 0.07 | 0.07 | 3.24 |
| capex per share | 0 | 0 | NaN |
ROE:
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -10.79 on 2024-10-31 Q1 from -14.19 on 2024-07-31 Q4, representing a change of 23.97%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.13 on 2024-10-31 Q1 from 0.18 on 2024-07-31 Q4, representing a change of -28.55%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to -0.49 on 2024-10-31 Q1 from -0.53 on 2024-07-31 Q4, representing a change of 6.94%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -0.01 which is lower than current price 0.08, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-21 18:00:00
HALIFAX, NS / ACCESS Newswire / January 21, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional administration, expanding access to testing for syphilis and HIV in Canada.
Sentiment: Positive
Publish Date: 2025-01-14 17:00:00
HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and high-quality result to be used in any health care setting.
Sentiment: Positive
Publish Date: 2025-01-09 18:00:00
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led by REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto) with funding from the Canadian Institute of Health Research (CIHR) and Indigenous Services Canada (ISC).
Sentiment: Positive
Publish Date: 2024-12-30 22:00:00
HALIFAX, NS / ACCESSWIRE / December 30, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended October 31, 2024. Corporate update During Q1 FY2025, MedMira has been continuing its regulatory work and clinical trials for its Reveal® G4 HIV-1/2 rapid test CLIA-waiver and with it made substantial progress on its FDA application.
Sentiment: Positive
Publish Date: 2024-12-24 12:00:00
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and syphilis in Canada. The single Reveal® TP (Syphilis) approval will follow soon after this more complex approval.
Sentiment: Positive
Publish Date: 2024-11-28 23:00:00
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval for its Reveal® G4 Rapid HIV-1/2 antibody test.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
